Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784524 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00784524 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 14 participants.
The verdict
NCT00784524, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving vaccine therapy together with aldesleukin may be a more effective treatment for metastatic breast cancer. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with aldesleukin works in treating women with metastatic breast cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL allogeneic large multivalent immunogen breast cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784524
The ClinicalTrials.gov registry entry for NCT00784524 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00784524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00784524 about?
NCT00784524 is a clinical study titled "Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca". RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving vaccine therapy together with aldesleukin may be a more effective treatment for metastatic breast cancer. PURPOSE: This p...
What is the current status of trial NCT00784524?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2008-09. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00784524?
The interventions under investigation include: aldesleukin (BIOLOGICAL), allogeneic large multivalent immunogen breast cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00784524?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.